All In Biotech

Drug Trial Radar · NCT05268666

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

A First-in-Human, Open-label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

126

Planned (sponsor's estimate)

Start

Apr 8, 2022

Primary completion

Dec 2024

Study completion Aug 2025

Sponsor

Lead sponsor
Jubilant Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Mar 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.

Conditions

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • JBI-802Drug

    LSD1/HDAC6 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum-Tolerated Dose (MTD)Time frame: 28-day cycle
  2. Investigator-Assessed ORR (Part 2)Time frame: Up to 30 days from the last dose of study drug

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute at HealthOne

    Denver, Colorado · Completed

  • The Christ Hospital

    Cincinnati, Ohio · Recruiting

  • Tennessee Oncology, PLLC

    Nashville, Tennessee · Completed

  • NEXT Virginia, LLC

    Fairfax, Virginia · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.